NCT02429466View on ClinicalTrials.gov

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

June 4, 2018

Study Completion Date

February 13, 2019

Conditions
Germ Cell TumorTestis CancerTesticular Cancer
Interventions
DRUG

Guadecitabine (SGI-110)

SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.

Trial Locations (2)

46202

Indiana University Hospital, Indianapolis

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

All Listed Sponsors
lead

Nasser Hanna

OTHER

NCT02429466 - Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors | Biotech Hunter | Biotech Hunter